Strengthening the medical device sales network in China through the acquisition of Itabashi Boeki as a subsidiary
First written in FY2021-Q3. 3 of 6 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AdvancedAnnual report
「Dalian Itabashi Medical Instruments Co., Ltd. ① Revenue ¥15,323 million ② Ordinary profit ¥4,177 million ③ Net income ¥3,100 million」
The 板橋貿易 group's Chinese medical-device sales network became established as a business foundation, and the revenue and profit results of Dalian Itabashi Medical Instruments Co., Ltd. were disclosed. - FY2022AdvancedAnnual report
「In Asia, demand for orthokeratology lenses and care products, supported by their high quality and the strength of their Japanese-made brands, remained strong. Synergies with the 板橋貿易 group, which became a wholly owned subsidiary in January 2021, were realized throughout the year and contributed to business growth.」
The 板橋貿易 group's Chinese sales network operated throughout the year, contributing to sales of orthokeratology lenses and care products and to growth in the Asian business. - FY2022-Q2RestatedAnnual report
「During the current quarter, sales by the Itabashi Boeki Group, which was made a wholly owned subsidiary in the previous consolidated fiscal year, remained strong, and sales of both orthokeratology lenses and care products progressed steadily.」
The strengthening of the Chinese sales network through the acquisition of 板橋貿易 as a wholly owned subsidiary, together with the sales impact of orthokeratology lenses and care products, continues. - FY2022-Q1AdvancedAnnual report
「During the current quarter, the sales network of the Itabashi Boeki Group, which was made a wholly owned subsidiary in the previous consolidated fiscal year, made a significant contribution to the increase in sales, and sales of both orthokeratology lenses and care products progressed steadily.」
Following the acquisition of 板橋貿易 as a wholly owned subsidiary, the Chinese sales network made a significant contribution to the increase in revenue for the quarter, with an impact on sales of orthokeratology lenses and care products. - FY2021AchievedAnnual report
「On the sales side, the company made 板橋貿易株式会社 a wholly owned subsidiary in January 2021, primarily to strengthen its sales capabilities in China, thereby acquiring a sales network for future market expansion.」
On 8 January 2021, the company made 板橋貿易 a wholly owned subsidiary and acquired a sales and technical support network for medical devices in China, including Dalian Itabashi Medical Instruments Co., Ltd. - FY2021-Q3First statedAnnual report
「At a meeting of the Executive Committee held on 17 December 2020, the company resolved to acquire shares in 板橋貿易株式会社 (hereinafter, 板橋貿易) and make it a subsidiary. Accordingly, the company entered into a share transfer agreement dated 17 December 2020, acquired the shares on 8 January 2021 and made the company a subsidiary.」
The company made 板橋貿易 a subsidiary on 8 January 2021 and launched measures to strengthen its expansion into the orthokeratology business and the Chinese market through its Chinese subsidiary's medical-device sales and technical-support divisions.